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Binding to the primary receptor CD4 induces conformational changes in the human immunodeficiency virus
type 1 (HIV-1) gp120 envelope glycoprotein that allow binding to the coreceptor (CCR5 or CXCR4) and
ultimately trigger viral membrane-cell membrane fusion mediated by the gp41 transmembrane envelope
glycoprotein. Here we report the derivation of an HIV-1 gp120 variant, H66N, that confers envelope glycoprotein resistance to temperature extremes. The H66N change decreases the spontaneous sampling of the
CD4-bound conformation by the HIV-1 envelope glycoproteins, thus diminishing CD4-independent infection.
The H66N change also stabilizes the HIV-1 envelope glycoprotein complex once the CD4-bound state is
achieved, decreasing the probability of CD4-induced inactivation and revealing the enhancing effects of soluble
CD4 binding on HIV-1 infection. In the CD4-bound conformation, the highly conserved histidine 66 is located
between the receptor-binding and gp41-interactive surfaces of gp120. Thus, a single amino acid change in this
strategically positioned gp120 inner domain residue influences the propensity of the HIV-1 envelope glycoproteins to negotiate conformational transitions to and from the CD4-bound state.
binding (17). The interaction of HIV-1 gp120 with CD4 is
accompanied by an unusually large change in entropy, which is
thought to indicate the introduction of order into the conformationally flexible unliganded gp120 glycoprotein (61). In the
CD4-bound state, gp120 is capable of binding CCR5 with high
affinity; moreover, CD4 binding alters the quaternary structure
of the envelope glycoprotein complex, resulting in the exposure of gp41 ectodomain segments (27, 45, 77, 92). The stability
of the intermediate state induced by CD4 binding depends
upon several variables, including the virus (HIV-1 versus HIV2/simian immunodeficiency virus [SIV]), the temperature, and
the nature of the CD4 ligand (CD4 on a target cell membrane
versus soluble forms of CD4 [sCD4]) (30, 73). For HIV-1
exposed to sCD4, if CCR5 binding occurs within a given period
of time, progression along the entry pathway continues. If
CCR5 binding is impeded or delayed, the CD4-bound envelope glycoprotein complex decays into inactive states (30). In
extreme cases, the binding of sCD4 to the HIV-1 envelope
glycoproteins induces the shedding of gp120 from the envelope
glycoprotein trimer (31, 56, 58). Thus, sCD4 generally inhibits
HIV-1 infection by triggering inactivation events, in addition to
competing with CD4 anchored in the target cell membrane
(63).
HIV-1 isolates vary in sensitivity to sCD4, due in some cases
to a low affinity of the envelope glycoprotein trimer for CD4
and in other cases to differences in propensity to undergo
inactivating conformational transitions following CD4 binding
(30). HIV-1 isolates that have been passaged extensively in

Human immunodeficiency virus type 1 (HIV-1), the cause of
AIDS (6, 29, 66), infects target cells by direct fusion of the viral
and target cell membranes. The viral fusion complex is composed of gp120 and gp41 envelope glycoproteins, which are
organized into trimeric spikes on the surface of the virus (10,
51, 89). Membrane fusion is initiated by direct binding of
gp120 to the CD4 receptor on target cells (17, 41, 53). CD4
binding creates a second binding site on gp120 for the chemokine receptors CCR5 and CXCR4, which serve as coreceptors
(3, 12, 19, 23, 25). Coreceptor binding is thought to lead to
further conformational changes in the HIV-1 envelope glycoproteins that facilitate the fusion of viral and cell membranes.
The formation of an energetically stable six-helix bundle by the
gp41 ectodomain contributes to the membrane fusion event (9,
10, 79, 89, 90).
The energy required for viral membrane-cell membrane fusion derives from the sequential transitions that the HIV-1
envelope glycoproteins undergo, from the high-energy unliganded state to the low-energy six-helix bundle. The graded transitions down this energetic slope are initially triggered by CD4
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T-cell lines (the tissue culture laboratory-adapted [TCLA] isolates) exhibit lower requirements for CD4 than primary HIV-1
isolates (16, 63, 82). TCLA viruses bind sCD4 efficiently and
are generally sensitive to neutralization compared with primary HIV-1 isolates. Differences in sCD4 sensitivity between
primary and TCLA HIV-1 strains have been mapped to the
major variable loops (V1/V2 and V3) of the gp120 glycoprotein (34, 42, 62, 81). Sensitivity to sCD4 has been shown to be
independent of envelope glycoprotein spike density or the intrinsic stability of the envelope glycoprotein complex (30, 35).
In general, HIV-1 isolates are more sensitive to sCD4 neutralization than HIV-2 or SIV isolates (4, 14, 73). The relative
resistance of SIV to sCD4 neutralization can in some cases be
explained by a reduced affinity of the envelope glycoprotein
trimer for sCD4 (57); however, at least some SIV isolates
exhibit sCD4-induced activation of entry into CD4-negative,
CCR5-expressing target cells that lasts for several hours after
exposure to sCD4 (73). Thus, for some primate immunodeficiency virus envelope glycoproteins, activated intermediates in
the CD4-bound conformation can be quite stable.
The HIV-1 envelope glycoprotein elements important for
receptor binding, subunit interaction, and membrane fusion
are well conserved among different viral strains (71, 91). Thus,
these elements represent potential targets for inhibitors of
HIV-1 entry. Understanding the structure and longevity of the
envelope glycoprotein intermediates along the virus entry
pathway is relevant to attempts at inhibition. For example,
peptides that target the heptad repeat 1 region of gp41 exhibit
major differences in potency against HIV-1 strains related to
efficiency of chemokine receptor binding (20, 21), which is
thought to promote the conformational transition to the next
step in the virus entry cascade. The determinants of the duration of exposure of targetable HIV-1 envelope glycoprotein
elements during the entry process are undefined.
To study envelope glycoprotein determinants of the movement among the distinct conformational states along the
HIV-1 entry pathway, we attempted to generate HIV-1 variants that exhibit improved stability. Historically, labile viral
elements have been stabilized by selecting virus to replicate
under conditions, such as high temperature, that typically
weaken protein-protein interactions (38, 39, 76, 102). Thus, we
subjected HIV-1 to repeated incubations at temperatures between 42°C and 56°C, followed by expansion and analysis of
the remaining replication-competent virus fraction. In this
manner, we identified an envelope glycoprotein variant, H66N,
in which histidine 66 in the gp120 N-terminal segment was
altered to asparagine. The resistance of HIV-1 bearing the
H66N envelope glycoproteins to changes in temperature has
been reported elsewhere (37). Here, we examine the effect of
the H66N change on the ability of the HIV-1 envelope glycoproteins to negotiate conformational transitions, either spontaneously or in the presence of sCD4. The H66N phenotype
was studied in the context of both CD4-dependent and CD4independent HIV-1 variants.
MATERIALS AND METHODS
Selection of heat-resistant virus. The pNL4.3-KB9 plasmid, which contains the
KB9 (36) envelope glycoproteins in the background of the NL4.3 (1) provirus,
was used to generate infectious HIV-1. 293T cells were transfected with 25 g of
the pNL4.3-KB9 plasmid by using a calcium phosphate transfection kit (Invitro-
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gen, Carlsbad, CA). After 10 h, medium was replaced, and virus-containing
supernatants were harvested 3 days later. After clarification by low-speed
(2,000 ⫻ g for 10 min) centrifugation, the amount of virus in the supernatant was
quantitated by a reverse transcriptase (RT) assay (70). Virus-containing supernatants were aliquoted and stored at ⫺80°C. For a selection of heat-resistant
viruses, 1G5 cells, which were derived from the Jurkat T-cell line and contain a
stably integrated luciferase gene under the control of the HIV-1 long terminal
repeat (2), were incubated overnight with 200,000 RT units of virus in 1 ml. Cells
were washed once, resuspended in 10 ml of growth medium, and kept in culture
at 37°C to allow virus replication. After 3 to 4 days or when the titer of virus
reached 500,000 RT units/ml, the supernatant was harvested, quantitated, and
stored at ⫺80°C. Aliquots of virus were thawed, adjusted for equivalent RT units,
and kept in a water bath set at a given temperature, ranging from 37°C to 56°C,
while a control aliquot was added directly to cells. At various time points,
aliquots were removed, cooled to room temperature, and added to 1G5 Jurkat T
cells. Cells were split every 3 to 4 days, and the titer of virus in the culture
medium was measured. Those cultures with a detectable viral titer and derived
from aliquots exposed the longest to a given temperature were expanded further,
whereas the rest were discarded. When the virus titer in the selected cultures
reached approximately 500,000 RT units/ml, culture media were collected, aliquoted, and kept at ⫺80°C. These samples served as the starting stocks for the
next round of selection. The incubation of virus at a given temperature, the
selection of a resistant virus population, and the expansion on 1G5 Jurkat T cells
were repeated for several cycles, with the temperature of selection or the duration of exposure increased at each cycle. Subsequent studies (37) determined
that the H66N change in gp120 was a determinant of decreased HIV-1 sensitivity
to temperature extremes.
Site-directed mutagenesis. Mutations in the HIV-1 env gene were introduced
by site-directed mutagenesis using the QuikChange protocol (Stratagene). The
H66N change was introduced into pSVIIIenv (32) plasmids expressing the
HXBc2, KB9, ADAfl, YU2, JR-FL, ADA N197S, or ADA ⌬V1/V2 envelope
glycoproteins. The ADAfl envelope glycoproteins are full-length ADA envelope
glycoproteins and differ from the previously reported ADA-HXBc2 chimeric
envelope glycoproteins (82). The HXBc2 envelope glycoproteins are X4-tropic;
the ADAfl, YU2, JR-FL, ADA N197S, and ADA ⌬V1/V2 envelope glycoproteins are R5-tropic. The KB9 envelope glycoproteins are dual-tropic. The ADA
N197S and ADA ⌬V1/V2 envelope glycoproteins are CD4-independent, R5
envelope glycoproteins derived from an ADA-HXBc2 chimeric envelope glycoprotein (43, 44). Complementary pairs of primers were used to introduce the
H66N mutation into the envelope expressor plasmids; the sequence of one such
primer is 5⬘-ATATGATACAGAGGTAAATAATGTTTGGGC-3⬘. To generate
envelope glycoproteins with a deletion of the gp41 cytoplasmic tail, a stop codon
was introduced just after the sequence encoding the transmembrane region by
using complementary pairs of primers; the sequence of one such primer is
5⬘-CCCTGCCTAACTCTAATTTACTATAGAAAGTACAGC-3⬘. The presence of the desired mutations and the absence of unintended changes were
confirmed by DNA sequencing of the entire Env-coding region. All plasmids
expressing the wild-type and mutant envelope glycoproteins were prepared using
a QIAFilter kit (Qiagen), quantified, and stored.
Production of recombinant HIV-1 reporter viruses. Recombinant HIV-1 encoding firefly luciferase and pseudotyped with the wild-type or mutant HIV-1
envelope glycoproteins was produced by cotransfecting 293T cells with a pSVIIIenv plasmid expressing the HIV-1 envelope glycoprotein variants, the
pCMV⌬P1⌬envpA plasmid, and pHIV-1Luc plasmid at a 1:2:2 weight ratio,
respectively, using Effectene reagent (Qiagen). The pCMV⌬P1⌬envpA plasmid
encodes the packaging components (Gag/Pol proteins) and the Tat protein of
HIV-1 (64). The pHIV-1Luc plasmid encodes a packageable HIV-1 vector that
is defective in all HIV-1 genes except tat and that expresses the luciferase
reporter gene (99). The viral stocks, which are capable of a single round of
infection, were harvested 2 to 3 days later, quantitated by an RT assay, aliquoted,
and stored at ⫺80°C.
Virus infection assay. Cf2Th cells coexpressing CD4 and one of the coreceptors CCR5 (Cf2Th-CD4/CCR5) or CXCR4 (Cf2Th-CD4/CXCR4) or expressing
only CCR5 (Cf2Th-CCR5) were seeded at a density of 8,000 cells/well in a
96-well plate and cultured overnight at 37°C. About 30,000 RT units of virus was
added to the cells the next day at 37°C in 200 l of medium, and the cells were
cultured for another 2 days. Medium was removed, and cells were lysed with 50
l of 1⫻ luciferase lysis buffer (Promega, Madison, WI). Luciferase assays were
performed, using D-luciferin salt as a substrate (BD Pharmingen, San Jose, CA),
with an EG&G Berthold microplate luminometer LB 96V (Berthold Technologies, Oak Ridge, TN).
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Transient expression of radiolabeled HIV-1 envelope glycoproteins and measurement of sCD4 binding and sCD4-induced shedding. 293T cells grown to 70%
confluence in 100-mm dishes were transfected with 3 g of an envelope glycoprotein-expressing plasmid DNA and 1 g of an HIV-1 Tat-expressing plasmid
DNA with Effectene transfection reagent (Qiagen). One day later, the medium
was removed, the cells were washed once with 10 ml of phosphate-buffered saline
(PBS), and 9 ml of labeling medium (10% heat-inactivated, dialyzed fetal bovine
serum [FBS]; 10 g/ml penicillin-streptomycin solution; 50 Ci/ml 35S-Express
protein labeling mix [Perkin Elmer, Waltham, MA]; and 2 mM L-glutamine in
Dulbecco’s modified Eagle medium [DMEM]) was added to the transfected
cells. The cells were incubated at 37°C for another day before the medium and
cells were harvested. Cells were detached from culture dishes by incubation with
2 ml of 5 mM EDTA in PBS for 5 min and washed with PBS before equal
amounts were aliquoted in duplicate to separate tubes. To one duplicate set of
tubes, sCD4 was added to final concentrations of 200 and 1,000 nM; to the
control set of tubes, medium without sCD4 was added. The tubes were incubated
at 37°C for 1 h. The cell culture medium was harvested, and gp120 glycoproteins
shed into the culture media were quantified by immunoprecipitation.
The cells were used to prepare lysates for the analysis of envelope glycoprotein
expression and processing. Cells were suspended in 1 ml cell lysis buffer (0.5 M
NaCl, 10 mM Tris, pH 7.5, 0.5% [vol/vol] NP-40, and a cocktail of protease
inhibitors) and incubated at 4°C for 30 min, with gentle agitation. The lysates
were cleared by centrifugation at 14,000 ⫻ g for 30 min at 4°C. The envelope
glycoproteins were precipitated from the supernatants with a mixture of sera
from HIV-1-infected individuals.
To measure sCD4 binding, approximately 5 ⫻ 105 293T cells transiently
expressing the HIV-1 envelope glycoproteins were incubated for 1 h at room
temperature or 37°C with serial dilutions of sCD4 or CD4-immunoglobulin (Ig)
in fluorescence-activated cell sorter (FACS) buffer (PBS-5% FBS). The cells
were washed three times with FACS buffer and then incubated for 1 h at room
temperature with either OKT4, a fluorescein isothiocyanate-conjugated antiCD4 antibody (eBiosciences, San Diego, CA) (for sCD4), or phycoerythrinconjugated rabbit anti-human IgG (Sigma, St. Louis, MO) (for CD4-Ig). The
cells were then washed three times with FACS buffer and analyzed with a
FACScan flow cytometer with CellQuest software (Becton Dickinson, Mountain
View, CA) and FLOWJO software (FlowJo, Ashland, OR).
Immunoprecipitation of envelope glycoproteins. Radiolabeled HIV-1 gp120
glycoproteins shed into supernatants after incubation of envelope glycoproteinexpressing cells with sCD4 were detected by precipitation with a mixture of sera
from HIV-1-infected individuals. Approximately 250 l of cell culture medium
was added to 80 l of 50% protein A-Sepharose beads (Amersham Pharmacia
Biotech, Piscataway, NJ), 5 l of 10% bovine serum albumin, and a mixture of
sera from HIV-1-infected individuals; DMEM with 10% FBS was added to bring
the total volume to 500 l. For precipitation of envelope glycoproteins from the
lysates of transfected 293T cells (see above), 900 l of cell lysate was incubated
with 100 l of 50% protein A-Sepharose beads, 10 l of 10% bovine serum
albumin, and 5 l of a mixture of sera from HIV-1-infected individuals. The
mixtures were incubated at 4°C for 2 to 3 h, and the Sepharose beads were then
washed three times with 1 ml of wash buffer (0.1% NP-40, 0.3 M NaCl, 50 mM
Tris-HCl [pH 7.5]) and once with 1 ml of PBS. The beads were mixed with gel
loading buffer and boiled for 5 min. Following the removal of the beads by
centrifugation, the supernatants were loaded on a 10% bis-Tris sodium dodecyl
sulfate (SDS)-polyacrylamide gel. The gel was enhanced with Autofluor (National Diagnostics, Atlanta, GA) for 45 min, dried at 80°C for 2 h, and exposed
to film or phosphor screen. The amounts of radiolabeled HIV-1 envelope glycoproteins precipitated were measured either by densitometric analysis of autoradiograms using Quantity One, v4.6.3, software (Bio-Rad, Philadelphia, PA) or
by use of a Storm PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
HIV-1 neutralization assay. Neutralization of virus infectivity was assessed by
incubating sCD4 and antibodies with recombinant, luciferase-expressing virus at
37°C for 1 to 2 h and then measuring entry into target cells. The different virus
mutants, at a concentration of 150 RT units/l, were incubated with serial
dilutions of sCD4 (final concentrations ranging from 0 to 500 nM) in a total
volume of 650 l and added to target cells in triplicate.
The neutralization of HIV-1 by monoclonal antibodies recognizing different
epitopes on the HIV-1 envelope glycoproteins was examined. These antibodies
(and their epitopes) include F105 (the gp120 CD4 binding site) (67, 85), 2G12
(gp120 outer-domain carbohydrate) (72, 87), and 2F5 (gp41 membrane-proximal
extracellular region) (15, 60). The CD4-induced (CD4i) antibodies (412d, 48d,
and 17b) recognize an epitope near the chemokine receptor binding site on the
CD4-bound conformation of gp120 (13, 84, 96). Recombinant HIV-1, at a concentration of 150 RT units/l, was incubated for 1 to 2 h with serial dilutions of
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these antibodies (final concentrations ranging from 0 to 167 nM) in a total
volume of 650 l at 37°C before being added to target cells to measure infectivity.
After 2 to 3 days in culture, the cells were lysed and assayed for luciferase activity.
The sensitivity of HIV-1 to inhibition by the CD4-mimetic compound NBD556 (52, 74, 103) was examined. The compound was dissolved in dimethyl sulfoxide to create 10 to 20 mM stock solutions and stored in aliquots at ⫺20°C. It
was then diluted to 1 mM in serum-free DMEM for use in assays. On the day of
infection, NBD-556 (1 to 100 M) was added to recombinant viruses (10,000 RT
units) in a final volume of 50 l and incubated at 37°C for 30 min. The medium
was removed from the target cells, which were then incubated with the virus-drug
mixture for 48 h at 37°C. The medium was then removed from each well, and
virus infection was assayed by lysing cells and measuring luciferase activity in the
cell lysate.
sCD4 activation and stability of the CD4-bound intermediate state. The effect
of sCD4 on activating the infectivity of HIV-1 was measured with Cf2Th-CCR5
cells. Recombinant HIV-1 at a concentration of 150 RT units/l was incubated
with different concentrations of sCD4 for 1 to 2 h at 37°C and added to Cf2ThCCR5 cells. After 2 to 3 days in culture, the cells were lysed and assayed for
luciferase activity.
To measure the effect of the H66N change on the stability of the CD4-bound
intermediate state of the HIV-1 envelope glycoproteins, 7.5 ⫻ 105 RT units/ml
of recombinant HIV-1 was divided into two 1-ml aliquots. To one aliquot, sCD4
was added to a final concentration of 200 nM; the other aliquot was left untreated. All virus preparations with and without sCD4 treatment were incubated
for 1 h at 37°C. After incubation, unbound sCD4 was removed by pelleting the
virus three times at 41,000 rpm in an SW-41 rotor for 30 min at 4°C in a
Beckman-Alegra centrifuge, followed by resuspension in DMEM with 10% FBS.
The washed virus was aliquoted and incubated at 37°C. At various time points,
aliquots were added to Cf2Th-CCR5 cells. Virus infectivity was measured by the
luciferase assay, as described above.
Binding of HIV-1 gp120 to CCR5. 293T cells were transfected with plasmids
expressing HIV-1 envelope glycoproteins with deletions of the gp41 cytoplasmic
tail. Cells were radiolabeled as described above. The supernatants were harvested and cleared by centrifugation (200 ⫻ g for 5 min at 4°C).
The amount of gp120 glycoprotein in the supernatants was quantitated by
immunoprecipitating serial dilutions of the media; precipitated proteins were
separated by SDS-polyacrylamide gel electrophoresis (PAGE) and analyzed by
densitometry. The gp120 concentrations in the supernatants were equalized by
dilution with DMEM. To one set of samples, sCD4 was added to a final concentration of 200 to 400 nM; the other set of samples was left untreated. All
samples were incubated at 37°C for 1 h and then added to 5 ⫻ 106 to 6 ⫻ 106
Cf2Th-CCR5 cells or kept at 4°C. The mixtures of supernatant and cells were
incubated at 4°C for 2 h. Cells were washed twice with PBS to remove unbound
gp120 and lysed with 1 ml cell lysis buffer. The bound gp120 was precipitated by
a mixture of sera from HIV-1-infected individuals and analyzed by SDS-PAGE
and densitometry. The input amount of gp120 in the CCR5-binding assay was
estimated in parallel by immunoprecipitation of an aliquot of cleared 293T cell
supernatant that was not incubated with Cf2Th-CCR5 cells but was instead kept
at 4°C.
Production and purification of HIV-1 gp120 glycoproteins. The wild-type and
mutant gp120 variants with C-terminal His6 epitope tags were expressed from
plasmids containing a codon-optimized env gene (GeneScript Corp., Piscataway,
NJ). The plasmids were transfected into 293F cells by using 293fectin reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Seven days
later, the supernatant containing the gp120 envelope glycoproteins was harvested
and filtered using 0.45-m filters. The supernatant was concentrated two- to
threefold by use of Centricon plus-80 filters (Amicon, Billerica, MA). Ni-nitrilotriacetic acid beads (Qiagen) were added to the concentrated supernatant and
incubated overnight at 4°C with gentle shaking. The supernatant/bead mixture
was poured into a small column, washed with 20 mM imidazole in buffer A (150
mM NaCl, 20 mM Tris-HCl, pH 7.4), and eluted by gravity flow with 200 mM
imidazole in buffer A. The eluant was concentrated with Centriprep-30 (Amicon)
and dialyzed with a 10,000-molecular-weight-cutoff dialysis cassette (Pierce,
Rockford, IL) in 20 mM Tris-HCl, pH 7.4, and 150 mM NaCl. The gp120
glycoproteins were stored at ⫺80°C.
Isothermal titration microcalorimetry. Isothermal titration calorimetry experiments were performed using a high-precision VP-ITC titration calorimetric
system from MicroCal, Inc. (Northampton, MA). The calorimetric cell (⬃1.4
ml), containing one of the gp120 variants dissolved in PBS (Roche Diagnostics
GmbH), pH 7.4, with 2% dimethyl sulfoxide, was titrated with sCD4 or NBD-556
dissolved in the same buffer. The concentration of gp120 was ⬃4 M, and the
concentration in the injection syringe was ⬃20 M of CD4 or between 120 and
150 M of NBD-556. All experiments were conducted at 25°C. The heat evolved
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upon injection of sCD4 or NBD-556 was obtained from the integral of the
calorimetric signal. The heat associated with the binding reaction was obtained
by subtracting the heat of dilution from the heat of reaction. The individual heats
were plotted against the molar ratio, and the values for the enthalpy change (⌬H)
and the association constant (Ka ⫽ 1/Kd, where Kd is the dissociation constant)
were obtained by nonlinear least-squares regression of the data.
SPR. Surface plasmon resonance (SPR) experiments were performed with a
Biacore 3000 biosensor system at 25°C. The gp120 ligand, either sCD4 or the 17b
antibody, was immobilized on research-grade CM5 sensor chips by the recommended standard amine coupling. Wild-type or mutant gp120 variants at different concentrations were injected and allowed to bind the ligand captured on the
surface of the sensor chip. To examine sCD4-induced binding of gp120 to the 17b
antibody, each gp120 variant at a concentration of 500 nM was incubated with 4
M sCD4 at 25°C for 1 h. The mixture was then injected and allowed to bind the
17b antibody on the sensor chip. All binding experiments were carried out with
HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% polysorbate 20). During the association phase, analytes were passed over the bufferequilibrated chip surface at a rate of 50 l/min. After the association phase,
bound analytes were allowed to dissociate for 5 min. The chip surface was then
regenerated by two injections of 10 mM glycine HCl (pH 2.5) at a flow rate of 50
l/min for 30 s. Association and dissociation values were calculated by numerical
integration and globally fit to a 1:1 interaction model using BiaEvaluation 3.0
software (Biacore).
Molecular modeling of the H66N gp120 mutant. The X-ray crystal structure
(M. Pancera, S. Majeed, E.-E. Ban, C.-C. Huang, L. Kong, J. E. Robinson, W. R.
Schief, J. Sodroski, R. Wyatt, and P. D. Kwong, unpublished data) of the V1/V2
and V3 loop-deleted HIV-1 gp120 glycoprotein with intact N and C termini in
complex with two-domain CD4 and the 48d Fab fragment was used as a starting
point for modeling. The gp120 glycoprotein with the H66N change was modeled
from this structure using Coot (24). Refinements were performed with Crystallography and NMR System (CNS) software (7, 8) to calculate the energies of the
wild-type (His 66) and mutant (Asn 66) gp120 molecules. Energy minimization
scripts were run on atoms within 5 Å of the C␣ atom in residue 66 or within 5 Å
of any atom in residue 66. The difference in energy between the mutant (Asn 66)
gp120 and the wild-type (His 66) gp120 ranged from 150 to 178 CNS units, with
the wild-type gp120 exhibiting greater stability (lower energy). To normalize the
CNS energy units, the CNS energy units for 20 peptide hydrogen bonds (each of
nominal energy, 1.9 kcal/mol) were calculated. These ranged from 80 to 152 CNS
units, with a mean of 105 units and a standard deviation of 24 units. Normalization of the CNS energy units based on these hydrogen bond energies suggested that the energy difference between wild-type and H66N gp120 is approximately 3 kcal/mol. Because of differences in preferred side-chain rotamers,
asparagine 66 makes one less hydrogen bond with glutamic acid 64 than histidine
66 (see Fig. S7 in the supplemental material). Calculation of the overall CNS
energy with glutamic acid 64 side-chain oxygen atoms removed showed a difference in energy of 114 CNS units between wild-type and H66N gp120. Thus, the
ring stacking interactions between histidine 66 and phenylalanine 210 and proline 212 confer approximately 2 kcal/mol greater stability on the wild-type gp120
glycoprotein, when in the CD4-bound conformation.

RESULTS
To identify stabilizing changes in the HIV-1 envelope glycoproteins, we passaged a molecularly cloned HIV-1, NL4.3KB9, while intermittently incubating the viruses at elevated
temperatures. The NL4.3-KB9 virus is derived from the NL4.3
virus but has its envelope glycoproteins replaced by those of
the pathogenic simian-human immunodeficiency virus KB9.
The NL4.3-KB9 starting virus stock was incubated at a given
temperature for different periods of time, cooled to room temperature, and added to 1G5 cells. The 1G5 cells are Jurkat T
cells that contain an integrated luciferase gene under the control of the HIV-1 long terminal repeat (2). Viruses that survived the most extreme temperatures were propagated and
reexposed to increased temperature, and the process was repeated. A control stock of NL4.3-KB9 virus was passaged in
parallel on 1G5 cells without heat selection. Once viruses that
exhibited altered temperature sensitivity emerged, the env
genes of these viruses and the control viruses were PCR am-

8367

plified from infected cells. Each amplified fragment was cloned
and sequenced. Comparison of the env sequences from heatselected and control viruses revealed the presence of specific
mutations in the former. Studies reported elsewhere (37) revealed that the observed differences in temperature sensitivity
of the HIV-1 envelope glycoproteins resulted from a single
change of histidine 66 to asparagine (H66N).
Due to immune selective pressure, the HIV-1 gp120 glycoprotein exhibits significant interstrain variation, particularly
within the surface-exposed variable loops (V1 to V5) (55, 75,
78, 80, 93). The more conserved gp120 segments have been
designated C1 to C5. Histidine 66 is located in the first conserved (C1) region of gp120, within a short disulfide loop
bounded by cysteines 54 and 74. Although the sequences
within this disulfide loop differ considerably between the
HIV-1 and HIV-2/SIV lineages, there is a high degree of conservation of certain residues within each of these lineages.
Histidine 66, for example, is invariant in all of the HIV-1 and
SIVcpz sequences currently deposited in the Los Alamos National Laboratory HIV Sequence Database (46) (see Fig. S1 in
the supplemental material).
Effect of the H66N change on sensitivity to neutralization by
sCD4. To investigate the effect of the H66N change on sensitivity of HIV-1 to neutralization by sCD4, this change was
introduced into the envelope glycoproteins derived from several HIV-1 strains, i.e., KB9, ADAfl, YU2, JR-FL, and HXBc2.
The HIV-1KB9 dual-tropic envelope glycoproteins were derived from a pathogenic simian-human immunodeficiency virus
passaged in monkeys (36, 68). The HIV-1ADA(fl), HIV-1YU2,
and HIV-1JR-FL viruses are primary, CCR5-using isolates.
HIV-1HXBc2 is a TCLA, CXCR4-using isolate.
Recombinant HIV-1 encoding luciferase was pseudotyped
with the wild-type and H66N variants of the above-described
envelope glycoproteins and used to infect Cf2Th canine thymic
epithelial cells expressing human CD4 and the appropriate
human chemokine receptor. The infections were carried out
after the viruses were incubated at 37°C for 1 h without treatment or with increasing concentrations of sCD4. The basal
levels of infection in the absence of sCD4 treatment were
similar for viruses with the wild-type and H66N envelope glycoproteins (see Fig. S2A in the supplemental material). As
expected (55, 75, 78, 80, 93), viruses with the wild-type HXBc2
envelope glycoproteins exhibited the greatest sensitivity to
sCD4, with a 90% inhibitory concentration (IC90) of approximately 1.2 nM (Fig. 1A). Recombinant HIV-1 viruses with the
wild-type envelope glycoproteins from the R5 primary isolates
were significantly more resistant to sCD4, with IC90 values
ranging from 14 to 80 nM (Fig. 1B to D). Viruses with the
dual-tropic KB9 envelope glycoproteins exhibited intermediate
levels of sCD4 sensitivity (IC90 of 3 nM) (Fig. 1E). Thus, as
previously reported (5, 16, 57, 82), viruses with envelope glycoproteins derived from TCLA and primary HIV-1 strains
differ in sCD4 sensitivity.
Viruses with the H66N envelope glycoproteins were more
resistant to sCD4 than viruses bearing the wild-type HIV-1
envelope glycoproteins. Depending on the particular envelope
glycoproteins, the degree of sCD4 resistance varied from approximately 7-fold to 33-fold. Thus, the H66N change confers
some degree of sCD4 resistance to viruses with a variety of
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FIG. 1. Sensitivity to sCD4 neutralization. (A to E) Single-round
recombinant viruses bearing either the wild-type envelope glycoproteins (HXBc2, ADAfl, YU2, JR-FL, or KB9) or the H66N-modified
envelope glycoproteins (KB9-H66N, YU2-H66N, JR-FL-H66N,
ADAfl-H66N, or HXBc2-H66N) were equalized based on RT activity
and incubated with serial dilutions of sCD4 at 37°C for 1 h. The viruses
were then added to Cf2Th cells expressing CD4 and the appropriate
coreceptor. Infectivity was assessed by measuring the luciferase activity
in the total cell lysate. Infectivity at each dilution of sCD4 tested is
shown as the percentage of infection seen in the absence of sCD4.
Data are representative of results from three independent experiments
performed in triplicate, with means and standard deviations indicated.

HIV-1 envelope glycoproteins, in the context of infection of
CD4-positive cells.
Effect of the H66N change on HIV-1 infection of CD4-negative cells. To examine the effect of the H66N change on
HIV-1 infection of CD4-negative, CCR5-expressing cells, the
recombinant viruses with wild-type or H66N R5 envelope glycoproteins were incubated with Cf2Th-CCR5 cells along with
different concentrations of sCD4. In the absence of sCD4, the
level of infection of the Cf2Th-CCR5 cells by any of the viruses
was near the background for the assay (Fig. 2). The addition of
sCD4 resulted in enhanced infection by viruses with the wildtype JR-FL envelope glycoproteins but not by viruses with the
wild-type ADAfl or YU2 envelope glycoproteins. The lack of
enhancement of the viruses with the wild-type ADAfl or YU2
envelope glycoproteins was not due to a lack of sCD4 binding
to the envelope glycoproteins, because the infectivity of these
viruses for CD4-positive target cells was markedly inhibited by
incubation with sCD4 in this same concentration range (Fig.
1B and C).
Recombinant viruses bearing the H66N envelope glycoproteins exhibited greater enhancement by sCD4 than viruses with
the respective wild-type envelope glycoproteins. As the H66N
and wild-type viruses were normalized by RT measurements
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FIG. 2. Effect of H66N on sCD4-induced HIV-1 infection of CD4⫺
CCR5⫹ cells. Single-round viruses bearing either the wild-type envelope glycoproteins (ADAfl, YU2, or JR-FL) or the H66N-modified
envelope glycoproteins (ADAfl-H66N, YU2-H66N, or JR-FL-H66N)
were equalized according to RT activity and incubated with serial
dilutions of sCD4 at 37°C for 1 h. The viruses were then added to
Cf2Th-CCR5 cells that do not express CD4, and infectivity was assessed by measuring the luciferase activity in the total cell lysate.
Infectivity at each dilution of sCD4 tested is shown as the percentage
of infection seen in the absence of sCD4. Infectivity of the viruses with
Cf2Th-CCR5 cells in the absence of sCD4 was close to the background
for the assay. Data are representative of results from three independent experiments performed in triplicate, with means and standard
deviations indicated.

and demonstrated nearly equivalent levels of infectivity with
Cf2Th-CD4/CCR5 cells (see Fig. S2A in the supplemental
material), we conclude that the H66N change results in an
increase in sCD4 enhancement of infection of CD4-negative,
CCR5-expressing target cells.
Effects of H66N on gp120 ligand binding and induction of
conformational changes. The above-described results suggest
that the H66N change facilitates the enhancing effects of sCD4
binding on HIV-1 infection, diminishes the negative consequences of sCD4 binding on infection, or both. To investigate
the first possibility, we used isothermal titration microcalorimetry to assess the effect of H66N on sCD4 binding to gp120 and
on the ability of sCD4 to induce conformational changes in
gp120. We studied the binding of sCD4 to the wild-type and
H66N gp120 glycoproteins from HIV-1KB9 (Table 1). The
H66N mutant gp120 exhibited a slight (⬃2-fold) decrease in
affinity for sCD4 compared with that of the wild-type gp120

TABLE 1. Thermodynamic values associated with
gp120-sCD4 interaction
gp120 protein

Kd (nM)

⌬G
(kcal/mol)a

⌬H
(kcal/mol)b

⫺T⌬S
(kcal/mol)c

KB9
KB9-H66N
ADA N197S
ADA N197S-H66N

11
21
25
116

⫺10.8
⫺10.5
⫺10.4
⫺9.5

⫺40.9
⫺39.6
⫺28.0
⫺19.0

⫹30.1
⫹29.1
⫹17.6
⫹9.5

a
b
c

⌬G, free energy change.
⌬H, enthalpy change.
T, temperature; ⌬S, entropy change.
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TABLE 2. SPR measurements of the effect of the H66N change on
gp120-sCD4 binding
gp120 protein

Kona (M⫺1 s⫺1)

KB9
KB9-H66N
ADA N197S
ADA N197S-H66N

1.1 ⫻ 10
1.1 ⫻ 104
9.3 ⫻ 103
7.3 ⫻ 103

a
b

4

Koffb (s⫺1)
⫺4

1.9 ⫻ 10
2.8 ⫻ 10⫺4
6.4 ⫻ 10⫺4
1.1 ⫻ 10⫺3

Kd (nM)

17
24
69
140

Kon, on-rate constant.
Koff, off-rate constant.

glycoprotein. Very small decreases in the magnitudes of the
entropic and enthalpic changes associated with sCD4 binding
were seen for the H66N gp120 glycoproteins, compared with
the values observed for the wild-type HIV-1KB9 gp120. The
slight reduction in affinity for sCD4 associated with the H66N
change was corroborated by SPR analysis (Table 2). Of note,
the slight difference in sCD4 affinity between the wild-type and
H66N HIV-1KB9 gp120 glycoproteins arises entirely from a
difference in off-rate of binding.
We wished to examine the effect of H66N on CD4 binding
by a gp120 envelope glycoprotein derived from a CD4-independent HIV-1 isolate, ADA N197S, which can enter CCR5expressing cells lacking CD4 (43, 44). The loss of a glycosylation site at asparagine 197 has been shown to allow the ADA
N197S envelope glycoproteins to bind CCR5 and to mediate
infection of CCR5-expressing cells without prior interaction
with CD4 (44). Similarly to our observations with the CD4dependent KB9 envelope glycoprotein, the H66N change in
the ADA N197S gp120 glycoprotein resulted in a reduction in
affinity for sCD4 (Tables 1 and 2). Compared with the values
observed for ADA N197S gp120, the magnitudes of the entropic and enthalpic changes associated with sCD4 binding to
the ADA N197S-H66N gp120 were decreased. As was observed for KB9 gp120, the reduction in affinity for sCD4 resulting from the H66N change in ADA N197S gp120 was
primarily due to an increased off-rate. Therefore, in both CD4dependent and CD4-independent envelope glycoproteins, the
H66N change slightly decreases affinity for CD4, apparently by
destabilizing the gp120-CD4 complex and allowing more-rapid
dissociation of gp120 and CD4.
A major functional consequence of CD4 binding to the
HIV-1 gp120 glycoprotein is the induction of a conformation
capable of binding the chemokine receptor CCR5 or CXCR4
(33, 50, 86, 94). To examine whether H66N influences this
induction, wild-type and H66N gp120 glycoproteins from HIV1YU2 were radiolabeled and incubated with Cf2Th-CCR5 cells
in the absence or presence of sCD4. After the cells were
washed and lysed, bound gp120 was detected by immunoprecipitation. In the presence of a high concentration of sCD4, the
wild-type and H66N gp120 glycoproteins bound to the CCR5expressing cells comparably (Fig. 3, middle). In control experiments, the Cf2Th-CCR5 cells were incubated with an antiCCR5 antibody, 2D7, to demonstrate the dependence of gp120
binding on the CCR5 protein (Fig. 3, top). In the absence of
sCD4, the wild-type YU2 gp120 glycoprotein bound at low but
detectable levels to the Cf2Th-CCR5 cells; this low level of
binding was not seen for the H66N gp120 glycoprotein (Fig. 3,
middle). These results suggest that the wild-type YU2 gp120
glycoprotein spontaneously assumes the CD4-bound confor-

FIG. 3. Effect of H66N on CCR5 binding. Radiolabeled YU2 and
YU2-H66N gp120 envelope glycoproteins were incubated with Cf2ThCCR5 cells in the presence (⫹) or absence (⫺) of 400 nM sCD4.
Bound and input gp120 glycoproteins were immunoprecipitated and
analyzed by SDS-PAGE. The percentage of the input gp120 bound to
the Cf2Th-CCR5 cells is indicated beneath each lane. In control experiments, the anti-CCR5 antibody 2D7 was included in the incubation
to demonstrate the dependence of gp120 binding on CCR5 (top).

mation more efficiently than the H66N counterpart. The H66N
change apparently destabilizes the CD4-bound conformation
in the absence of CD4 but does allow efficient CCR5 binding
following CD4 engagement.
Effect of H66N on CD4-independent HIV-1 infection. We
wished to examine the effect of the H66N change on infection
by CD4-independent HIV-1. Recombinant HIV-1 viruses
bearing the ADA N197S or ADA N197S-H66N envelope glycoproteins were compared with respect to their abilities to
infect Cf2Th-CD4/CCR5 and Cf2Th-CCR5 cells (Fig. 4A).
Both viruses efficiently infected Cf2Th-CD4/CCR5 cells. Con-

FIG. 4. Effect of the H66N change on CD4-independent CCR5
binding and infection. (A) The infectivity of recombinant, luciferaseexpressing viruses with the ADA N197S CD4-independent envelope
glycoproteins or the ADA N197S-H66N envelope glycoproteins was
measured using Cf2Th-CD4/CCR5 or Cf2Th-CCR5 cells. The means
and standard deviations of infectivity, reported as relative luciferase
units (RLU), from a representative experiment performed in triplicate
are shown. (B) Radiolabeled ADA N197S or ADA N197S-H66N
gp120 envelope glycoproteins were incubated with control Cf2Th cells
or Cf2Th-CCR5 cells in the presence (⫹) or absence (⫺) of 200 nM
sCD4. Bound gp120 and input gp120 were immunoprecipitated and
separated by SDS-PAGE.
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FIG. 5. Effect of H66N on HIV-1 neutralization by monoclonal antibodies. Single-round recombinant viruses bearing the ADA N197S or ADA
N197S-H66N envelope glycoproteins were incubated for 1 h at 37°C with monoclonal antibodies directed against a gp120 carbohydrate-dependent
epitope (2G12), the gp120 CD4 binding site (F105), the gp41 membrane-proximal external region (2F5), and gp120 CD4i epitopes (48d, 412d, and
17b). Viruses were then added to Cf2Th-CD4/CCR5 cells, and infection was measured by assaying luciferase activity in the target cell lysate. The
infectivity relative to that seen in the absence of antibody is reported. Data are representative of results from three independent experiments
performed in triplicate, with means and standard deviations indicated.

sistent with the results obtained with CD4-dependent HIV-1
envelope glycoproteins, the H66N change exerted only a small
effect on the efficiency of infection of cells expressing CD4 and
a chemokine receptor. In contrast, although viruses with the
ADA N197S envelope glycoproteins efficiently infected Cf2ThCCR5 cells, as expected (44), no infection of these CD4-negative cells by viruses with the ADA N197S-H66N envelope
glycoproteins was detected. Thus, the H66N change eliminates
the ability of otherwise CD4-independent envelope glycoproteins to mediate infection of target cells lacking CD4, even
though the ability to infect CD4-expressing cells is retained.
The gp120 glycoproteins of CD4-independent HIV-1 variants can efficiently bind the chemokine receptor, without prior
interaction with CD4 (44). To examine the effect of the H66N
change on this process, radiolabeled ADA N197S and ADA
N197S-H66N gp120 glycoproteins were incubated with Cf2ThCCR5 cells in the absence or presence of sCD4. Studies using
CCR5 ligands have demonstrated that gp120 binding to
Cf2Th-CCR5 cells is dependent upon CCR5 (86, 94). Consistent with this, no gp120 binding to Cf2Th cells that do not
express CCR5 was detected in either the presence or the absence of sCD4 (Fig. 4B). In the absence of sCD4, the ADA
N197S gp120 glycoprotein, but not the ADA N197S-H66N
gp120 glycoprotein, bound the Cf2Th-CCR5 cells. Both gp120
glycoproteins bound the Cf2Th-CCR5 cells efficiently following incubation with sCD4, with a mild decrease in binding for
the ADA N197S-H66N gp120 compared with that for the
ADA N197S glycoprotein. These results suggest that the H66N
change decreases the ability of the ADA N197S gp120 glycoprotein to bind CCR5 spontaneously but does not prevent
CCR5 binding once CD4 is engaged.
The change in asparagine 197 in the ADA N197S mutant
removes a glycan from the V1/V2 stem, thereby increasing the
flexibility of the gp120 V1/V2 variable loops and contributing
to CD4 independence (44). A CD4-independent phenotype
can also be achieved by deleting the V1 and V2 variable loops
of the ADA gp120 glycoprotein (43). To examine whether the

phenotype of H66N is dependent on the integrity of the gp120
V1/V2 loops, the H66N change was introduced into an HIV-1
envelope glycoprotein, ADA ⌬V1/V2, in which the gp120 V1
and V2 loops were deleted. As shown in Fig. S3A in the
supplemental material, viruses with the ADA ⌬V1/V2 envelope glycoproteins efficiently infected Cf2Th-CCR5 cells, as
expected (43). However, the infectivity of viruses with the
ADA ⌬V1/V2-H66N envelope glycoproteins was significantly
lower using these cells. We conclude that the H66N change
decreases the ability of CD4-independent HIV-1 envelope glycoproteins to infect CD4-negative cells expressing CCR5 and
that this phenotype does not depend on the presence of the
gp120 V1 and V2 variable loops.
Effect of the H66N change on antibody recognition and
neutralization. Distinct conformations of the HIV-1 gp120 glycoproteins are recognized by particular groups of monoclonal
antibodies. For example, CD4i antibodies recognize the CD4bound conformation of HIV-1 gp120 (13, 84, 96), whereas
most CD4 binding site antibodies recognize conformations of
gp120 other than that induced by CD4 binding (97). Because
antibody binding to the HIV-1 envelope glycoprotein leads to
neutralization (40, 65, 69, 88, 98), we assessed the conformational state of the ADA N197S and ADA N197S-H66N envelope glycoproteins by measuring the sensitivities of viruses with
these envelope glycoproteins to neutralization by several
monoclonal antibodies. Viruses with the ADA N197S and
ADA N197S-H66N envelope glycoproteins exhibited similar
degrees of sensitivity to the carbohydrate-directed antibody
2G12 (72, 87) and to F105, an antibody directed against the
CD4 binding site of gp120 (67, 85) (Fig. 5). The viruses with
the ADA N197S envelope glycoproteins were slightly more
sensitive to neutralization by the 2F5 antibody than viruses
with the ADA N197S-H66N envelope glycoproteins. The 2F5
antibody recognizes a membrane-proximal epitope in the gp41
ectodomain (9, 15, 60).
In contrast to the results with the antibodies described
above, the viruses with the ADA N197S-H66N envelope gly-
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coproteins were significantly more resistant to neutralization
by three CD4i antibodies, 48d, 412d, and 17b (Fig. 5). Because
of steric constraints, HIV-1 neutralization by CD4i antibodies
must occur prior to the engagement of CD4 on the target cell
by virus (49, 83). Thus, our results suggest that, in the absence
of bound ligand, the ADA N197S-H66N envelope glycoproteins on the virus are recognized less efficiently than the ADA
N197S envelope glycoproteins by CD4i antibodies.
To obtain more quantitative information on the effect of the
H66N change on recognition by CD4i antibodies, we used an
SPR assay to measure the binding of gp120 glycoproteins to
the 17b antibody captured on a Biacore chip. In the experiment
with results shown in Fig. S4A in the supplemental material,
the same concentrations of ADA N197S and ADA N197SH66N gp120 glycoproteins were incubated in the absence or
presence of sCD4 prior to exposure to the captured 17b antibody. In the absence of sCD4, the binding of the ADA N197SH66N gp120 glycoprotein to the 17b antibody was much lower
than that of the ADA N197S glycoprotein. The H66N change
reduced the affinity of the ADA N197S gp120 glycoprotein for
the 17b antibody by more than 60-fold (see Fig. S4B in the
supplemental material). This decreased affinity resulted from a
slower association between gp120 and 17b as well as a faster
dissociation of the complex. Similar results were obtained for
the wild-type and H66N variants of the KB9 gp120 glycoprotein, which is a CD4-dependent envelope glycoprotein (see
Fig. S4C in the supplemental material). Thus, in the absence of
sCD4, HIV-1 gp120 with the H66N change is recognized only
weakly by the 17b antibody. In the presence of sCD4, however,
the ADA N197S-H66N gp120 glycoprotein bound the 17b antibody nearly as efficiently as the ADA N197S glycoprotein
(see Fig. S4B in the supplemental material).
In summary, the H66N change decreases the efficiency with
which unliganded HIV-1 gp120 samples the CD4-bound conformation recognized by CCR5 and the CD4i antibodies.
Effects of H66N on sensitivity of CD4-independent envelope
glycoproteins to sCD4. The sensitivity of CD4-independent
viruses to neutralization by sCD4 was examined. These experiments were conducted with both CD4-positive and CD4-negative target cells.
The basal levels of infectivity of viruses with the ADA N197S
and ADA ⌬V1/V2 envelope glycoproteins and their H66N
counterparts were comparable with Cf2Th-CD4/CCR5 target
cells (see Fig. S2B in the supplemental material). Both twodomain and four-domain sCD4 proteins inhibited the ADA
N197S-H66N viruses less efficiently than the ADA N197S viruses (Fig. 6A and data not shown). In fact, mild enhancement
of the virus with the ADA N197S-H66N envelope glycoproteins was evident at low concentrations of sCD4. Likewise, the
viruses with the ADA ⌬V1/V2-H66N envelope glycoproteins
were significantly more resistant to sCD4 than the viruses with
the ADA ⌬V1/V2 envelope glycoproteins (see Fig. S3B in the
supplemental material). Thus, H66N confers a degree of sCD4
resistance to both CD4-dependent and CD4-independent
HIV-1 viruses in the course of infection of CD4-expressing
target cells.
In CD4-negative target cells expressing only CCR5, the
basal levels of infection of the viruses with the ADA N197S
and ADA ⌬V1/V2 envelope glycoproteins were significantly
higher than those of viruses with the H66N-modified envelope
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FIG. 6. Effect of H66N on sCD4 sensitivity of CD4-independent
viruses. (A) Single-round recombinant viruses carrying either the ADA
N197S or the ADA N197S-H66N envelope glycoproteins were incubated with serial dilutions of four-domain sCD4 at 37°C for 1 h.
Infectivity was measured with Cf2Th-CD4/CCR5 cells and is reported
at each dilution of sCD4 as the percentage of infectivity observed
without sCD4 treatment of the viruses. Data are representative of
results from three independent experiments performed in triplicate,
with means and standard deviations indicated. (B) Single-round recombinant viruses carrying the ADA N197S or ADA N197S-H66N
envelope glycoproteins were incubated with serial dilutions of fourdomain sCD4 at 37°C for 1 h. The infectivity of the viruses was
measured with Cf2Th-CCR5 cells. Infectivity at each dilution of sCD4
is given as the percentage of infectivity observed without sCD4. Data
are representative of results from three independent experiments performed in triplicate, with means and standard deviations indicated.
(C) Single-round recombinant viruses bearing the ADA N197S or
ADA N197S-H66N envelope glycoproteins were incubated with (⫹) or
without (⫺) 200 nM sCD4 at 37°C for 1 h. Unbound sCD4 was
removed by pelleting virus at 41,000 rpm in an SW-41 rotor for 30 min
at 4°C. Pelleted virus was resuspended in 10 volumes of medium
without sCD4 and repelleted twice to ensure removal of unbound
sCD4. Virus was then resuspended in medium and incubated at 37°C
for different amounts of time before an aliquot was removed and
added to Cf2Th-CCR5 cells to measure infectivity. Data are representative of results from three independent experiments performed in
triplicate, with means and standard deviations indicated.
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FIG. 7. Effect of H66N on sCD4 binding and induction of gp120 shedding. (A) 293T cells transiently expressing cytoplasmic-tail-deleted ADA
N197S, ADA N197S-H66N, KB9, or KB9-H66N envelope glycoproteins were incubated at 37°C for 1 h with sCD4 at the indicated concentrations.
After the cells were washed, the bound sCD4 was detected by FACS analysis with OKT4, a fluorescein isothiocyanate-conjugated anti-CD4
antibody. The mean fluorescence intensity (MFI) values at different sCD4 concentrations are shown. Mock-transfected cells (Mock) were included
as a negative control. (B) 293T cells expressing the HIV-1 envelope glycoproteins described for panel A were incubated with 50 g/ml 2G12
antibody. After the cells were washed, the bound antibody was detected with phycoerythrin-conjugated rabbit anti-human IgG. (C) 293T cells
transiently expressing cytoplasmic-tail-deleted KB9 or KB9-H66N envelope glycoproteins or ADA N197S or ADA N197S-H66N envelope
glycoproteins were radiolabeled and incubated either in the absence of sCD4 or with 200 or 1,000 nM sCD4 at 37°C for 1 h. The gp120 shed into
the supernatant was precipitated by a polyclonal mixture of sera from HIV-1-infected individuals and analyzed by SDS-PAGE.

glycoproteins (Fig. 4A; also see Fig. S3C in the supplemental
material). Incubation with sCD4 neutralized the viruses with
the ADA N197S and ADA ⌬V1/V2 envelope glycoproteins but
enhanced the infection of viruses with the ADA N197S-H66N
and ADA ⌬V1/V2-H66N envelope glycoproteins (Fig. 6B; also
see Fig. S3C in the supplemental material). Two-domain sCD4
and four-domain sCD4 exhibited similar effects in this assay
(data not shown). In the setting of CD4-independent infection,
the potential inhibitory effects of sCD4 resulting from competition with membrane-bound CD4 for gp120 binding are eliminated. Thus, the observed sCD4 inhibition of the CD4-independent viruses with the ADA N197S and ADA ⌬V1/V2
envelope glycoproteins results solely from detrimental effects
of sCD4 binding on these envelope glycoproteins. The H66N
change apparently prevents or diminishes these detrimental
effects and reveals the activating effects of sCD4 binding on
virus entry. The sCD4 activation of infection of CD4-negative
cells by CD4-independent viruses with the H66N change is
reminiscent of that seen for viruses with natural HIV-1 envelope glycoproteins modified by H66N (Fig. 2).
Stability of the sCD4-induced state of the viral envelope
glycoproteins. The above-described studies support the existence of both positive and negative effects of sCD4 binding on
HIV-1 entry; the phenotypes of the H66N variants provided an
opportunity to examine the stability of the sCD4-induced envelope glycoprotein states. Recombinant viruses with the ADA
N197S or ADA N197S-H66N envelope glycoproteins were incubated with sCD4 for 1 h at 37°C, and then the viruses were
pelleted and washed repeatedly to ensure removal of sCD4
from the medium. The resuspended viruses were incubated at
37°C and, at different times, added to Cf2Th-CCR5 cells. The
resultant levels of infection are shown in Fig. 6C. In agreement
with the above-described observations, sCD4 enhanced the
infection of viruses with the ADA N197S-H66N envelope gly-

coproteins by 10-fold but inhibited infection by viruses with the
ADA N197S envelope glycoproteins by more than 40-fold. The
activated state of the ADA N197S-H66N envelope glycoproteins persisted for at least 3 h, the duration of the experiment.
The inhibitory effect of sCD4 on viruses with the ADA N197S
envelope glycoproteins occurred by the time of the first measurement of infection and persisted thereafter. Thus, the
sCD4-activated state of the ADA N197S-H66N envelope glycoproteins and the sCD4-induced, functionally inactivated
state of the ADA N197S envelope glycoproteins are both longlived.
Effect of the H66N change on sCD4 binding to the envelope
glycoprotein trimer and induction of gp120 shedding. The
above-described results suggest that the major effect of the
H66N change on the resistance of HIV-1 to sCD4 neutralization is mediated by stabilization of a sCD4-induced activated
form of the envelope glycoproteins, minimizing the probability
of transitions to less functional states. To examine this possibility further, we studied the binding of sCD4 to HIV-1 envelope glycoprotein trimers expressed on the surface of 293T
cells. The gp41 cytoplasmic tail was deleted from these envelope glycoproteins to increase cell surface expression (22, 26,
31, 56, 58, 59). The levels of binding of sCD4 to the ADA
N197S and ADA N197S-H66N envelope glycoproteins at 37°C
were similar (Fig. 7A). A control experiment using the 2G12
antibody indicated that the levels of cell surface expression of
the two envelope glycoproteins were comparable (Fig. 7B). We
conclude that minimal differences in binding of sCD4 exist
between the ADA N197S and ADA N197S-H66N trimeric
envelope glycoproteins, corroborating the results obtained
with monomeric gp120 variants (see above). Additional experiments conducted at room temperature with the KB9 and
ADA N197S envelope glycoproteins and their H66N-modified
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FIG. 8. Effect of a CD4-mimetic compound, NBD-556, on virus
infectivity. Single-round recombinant viruses bearing the KB9 or KB9H66N envelope glycoproteins (A and B), the ADAfl or ADAfl-H66N
envelope glycoproteins (C and D), or the ADA N197S or ADA N197SH66N envelope glycoproteins (E and F) were incubated with serial
dilutions of NBD-556. Infectivity was measured using Cf2Th-CD4/
CCR5 (A, C, and E) and Cf2Th-CCR5 (B, D, and F) cells. Infectivity
is reported as the percentage of infection observed in the absence of
the compound. Data are representative of results from three independent experiments performed in triplicate, with means and standard
deviations indicated.

counterparts yielded similar results (see Fig. S5 in the supplemental material).
One detrimental effect of sCD4 binding is the shedding of
gp120 from the HIV-1 envelope glycoprotein trimer (22, 26,
31, 56, 58, 59). To test whether the H66N change affects the
propensity of the HIV-1 envelope glycoproteins to shed gp120
in response to CD4 binding, we expressed radiolabeled functional envelope glycoproteins on the surface of 293T cells. The
gp41 cytoplasmic tail was removed from these envelope glycoproteins to enhance cell surface expression (28, 101). Cells
expressing KB9, KB9-H66N, ADA N197S, and ADA N197SH66N envelope glycoproteins were incubated with different
concentrations (200 and 1,000 nM) of sCD4 at 37°C for 1 h.
Media were harvested and examined for shed gp120 by immunoprecipitation with a mixture of sera from HIV-1-infected
individuals. The addition of sCD4 resulted in an increase in the
shedding of gp120 into the medium. The H66N change in both
the KB9 and ADA N197S envelope glycoproteins decreased
the amount of shed gp120 (Fig. 7C). Expression levels and
processing efficiencies of the various envelope glycoproteins
were equivalent (see Fig. S6 in the supplemental material).
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These results suggest that the H66N change allows efficient
sCD4 binding to the HIV-1 envelope glycoprotein trimer but
decreases the degree of gp120 shedding consequent to sCD4
binding.
Effects of the H66N change on susceptibility to a smallmolecule CD4 mimic. NBD-556 is a low-molecular-weight
compound that can induce conformational changes in the
HIV-1 gp120 glycoprotein similar to those that occur upon
CD4 binding (52, 74, 103). NBD-556 can enhance HIV-1 infection of CD4-negative, CCR5-positive cells and weakly inhibits infection of CD4-expressing cells (52, 74, 103).
The effects of NBD-556 on the infectivity of viruses with the
wild-type KB9 or KB9 H66N envelope glycoproteins were examined using Cf2Th-CD4/CCR5 and Cf2Th-CCR5 target
cells. NBD-556 inhibited the infection of viruses with the KB9
envelope glycoproteins in Cf2Th-CD4/CCR5 cells but did not
significantly affect the infectivity of viruses with the KB9-H66N
envelope glycoproteins (Fig. 8A). With the CD4-negative
Cf2Th-CCR5 cells, NBD-556 dramatically enhanced infection
of viruses bearing the wild-type KB9 envelope glycoproteins
but did not affect the infectivity of viruses with the KB9-H66N
envelope glycoproteins (Fig. 8B). These results indicate that
the H66N change renders the HIV-1 envelope glycoproteins
resistant to both the negative and the positive effects of NBD556 on viruses with the corresponding wild-type envelope glycoproteins.
One explanation for the above-described observations is that
the H66N change interferes with the binding of NBD-556 to
the gp120 glycoprotein. To test this, isothermal titration microcalorimetry studies were conducted with NBD-556 and the
wild-type and H66N gp120 glycoproteins from the KB9 HIV-1
strain (Table 3). The H66N change in gp120 reduced the NBD556 binding affinity to below the detection limits of the assay,
explaining the resistance of the virus with the KB9 H66N
envelope glycoproteins to the effects of NBD-556. This result is
also consistent with the observations made using another virus
with the CD4-dependent ADA envelope glycoproteins, in
which the H66N change rendered the virus resistant to the
effects of NBD-556 (Fig. 8C and D). In contrast, for the CD4independent ADA N197S envelope glycoproteins, where removal of a sugar in the V1/V2 stem allows CCR5 binding
without prior binding to CD4 (43), NBD-556 binding and entry
enhancement were not eliminated by the H66N change (Fig.
8E and F; Table 3). Thus, histidine 66 promotes the transition
of free gp120 into the CD4-bound conformation, a process that
contributes to the ability of NBD-556 to bind gp120 and induce
this conformation. The CD4-independent gp120 glycoprotein
has a greater propensity to make the transition into the CD4-

TABLE 3. Thermodynamic values associated with the binding of
gp120 and NBD-556
gp120 protein

Kd (M)

⌬G
(kcal/mol)

⌬H
(kcal/mol)

⫺T⌬Sa
(kcal/mol)

KB9
KB9-H66N
ADA N197S
ADA N197S-H66N

1.7
NBb
0.40
0.64

⫺7.8
NB
⫺8.7
⫺8.4

⫺22.6
NB
⫺12.0
⫺13.8

⫹14.8
NB
⫹3.3
⫹5.4

a
b

T, temperature; ⌬S, entropy change.
NB, no detectable binding.
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bound state than the CD4-dependent envelope glycoprotein.
As a likely consequence, the H66N change is less effective in
preventing the sampling of the CD4-bound conformation by
the CD4-independent envelope glycoprotein.
DISCUSSION
The H66N gp120 variant of HIV-1KB9 was derived by repeated selection of viruses by extremes of temperature; the
effect of the change in histidine 66 on the temperature stability
of HIV-1 has been described elsewhere (37). Here, we demonstrate that the H66N change in gp120 affects several of the
biological properties of HIV-1 related to the induction of the
CD4-bound state and the functional consequences of CD4
binding. The phenotypic effects of the H66N change in the
envelope glycoproteins derived from several different HIV-1
strains were similar. This observation and the highly conserved
nature of histidine 66 (see Fig. S1 in the supplemental material) support the generality of the results and suggest that
HIV-1 strains have conserved mechanisms whereby changes in
receptor binding trigger conformational transitions. Some of
the CD4-induced conformational transitions, such as those
that allow CCR5 binding or result in the exposure of the HR1
groove in the gp41 ectodomain, play positive roles in infection
(12, 27, 45). Other CD4-induced transitions lead to inactivation of the HIV-1 envelope glycoprotein trimer and, in extreme
cases, involve the shedding of gp120 (30, 31, 56).
For most wild-type, primary HIV-1 envelope glycoproteins,
competence for CCR5 binding and priming of the gp120-gp41
interaction occur only rarely in a spontaneous fashion; thus,
CD4 binding is required to allow these events, and virus entry,
to proceed (17). CD4-independent HIV-1 variants generated
in the laboratory negotiate these transitions spontaneously,
thus bypassing the need for CD4 binding (43, 44). The H66N
change reverts the CD4-independent envelope glycoproteins
back to envelope glycoproteins with CD4-dependent phenotypes. This reversion is evident in a decrease in spontaneous
gp120 binding to CCR5; in reduced infection of CD4-negative,
CCR5-expressing cells; and in decreased sensitivity to CD4i
antibodies, which recognize the CD4-bound conformation of
gp120 (13, 84, 96). These properties suggest that the unliganded CD4-independent envelope glycoproteins with asparagine
66 spontaneously sample the CD4-bound conformation less
than their counterparts with histidine 66. This implies that, in
the absence of sCD4, the H66N change either destabilizes the
CD4-bound conformation or stabilizes unliganded gp120 conformations other than the CD4-bound state. We favor the
former model for two reasons: (i) it is more consistent with our
observation that the H66N change selectively decreases sensitivity to neutralization by CD4i antibodies and does not affect
sensitivity to the F105 CD4 binding site antibody, and (ii) it
proposes a positive function for the highly conserved histidine
66, i.e., stabilization of the spontaneously sampled CD4-bound
conformation. Such stabilization could assist the flexible, unliganded HIV-1 gp120 glycoprotein to make secondary contacts
with CD4 after the initial, weak contact of the two molecules
(27, 45, 77, 92). This explanation is consistent with the observation that alteration of histidine 66 primarily increases the
dissociation of gp120-sCD4 complexes, with no apparent effect
on the rate of association of the two proteins.
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Both CD4-dependent and CD4-independent HIV-1 envelope glycoproteins with the H66N change exhibited decreased
susceptibility to the detrimental effects of sCD4 on virus infection. Some part of this resistance to sCD4 inhibition may arise
as a consequence of the small differences in ability to bind CD4
between wild-type and H66N gp120 glycoproteins. If the ⬃2fold difference in CD4-binding affinity between monomeric
wild-type and H66N gp120 glycoproteins applies, the levels of
occupancy of the envelope glycoprotein trimers should be similar at high CD4 concentrations. Indeed, the levels of binding
of sCD4 to wild-type and H66N envelope glycoprotein complexes expressed on cell surfaces were indistinguishable. These
and other results suggest that the H66N envelope glycoproteins differ from their unaltered counterparts in the consequences of CD4 binding. The CD4-bound HIV-1 envelope
glycoproteins represent metastable intermediates in the virus
entry process and make further transitions that either promote
virus entry (activation pathway) or lead to nonfunctional states
(inactivation pathway[s]) (30, 31, 56). The variables that determine which of these pathways predominates are still being
elucidated but presumably include the availability and binding
affinity of the chemokine receptor and the intrinsic strength of
the interactions that stabilize the CD4-bound state of the envelope glycoprotein trimer. It is noteworthy that when CD4
and CCR5 were present at high concentrations on the target
cells, there were minimal differences in infectivity of viruses
with unmodified and H66N envelope glycoproteins. In contrast, with CD4⫺ CCR5⫹ target cells, when sCD4 was first
incubated with virus so that the time between CD4 binding and
chemokine receptor binding was prolonged, dramatic differences in infectivity between the wild-type and H66N viruses
were evident. Whereas the wild-type viruses were inactivated
by sCD4 under these circumstances, infection by viruses with
the H66N envelope glycoproteins was enhanced. This observation suggests that the H66N change may decrease the efficiency of envelope glycoprotein transitions to less functional
states, thus favoring transitions to membrane-fusogenic states
promoted by chemokine receptor binding. In other studies,
wild-type HIV-1 envelope glycoproteins induced to assume the
CD4-bound conformation at a distance from a target cell were
shown to undergo a short-lived activation followed by irreversible inactivation (30). By limiting the ability of the HIV-1
envelope glycoproteins to assume the full CD4-bound state,
the H66N change may decrease the likelihood of negotiating
transitions into inactive states. This model is consistent with
the H66N envelope glycoprotein being selected on the basis of
improved temperature stability of the virus (37). Thus, resistance to generic destabilizing influences, such as temperature
extremes, can be achieved by avoidance of the labile CD4bound conformation.
The other interesting phenotype associated with the H66N
change in CD4-dependent envelope glycoproteins is resistance
to the CD4-mimetic compound NBD-556. This drug inhibits
virus entry into cells by competitive inhibition of CD4 binding
(103) and by prematurely triggering metastable activated envelope glycoprotein states that decay into inactive forms (30).
Binding of NBD-556 to gp120 induces conformational changes
similar to those associated with CD4 binding, albeit to a lesser
extent (66). When introduced into the gp120 glycoprotein of a
CD4-dependent virus, the H66N change completely eliminated
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binding to NBD-556, whereas this change only slightly reduced
binding affinity for CD4 itself. Apparently, the contribution of
histidine 66 to the achievement of the CD4-bound state is
critical for the ability of a small molecule like NBD-556 to
induce this state in a CD4-dependent envelope glycoprotein.
Presumably, the greater number of gp120 contacts made by
CD4 compensates more effectively for the loss of the histidine
66 contribution to the gp120 transition to the CD4-bound
state.
Of interest, the H66N derivative of a gp120 glycoprotein
from a CD4-independent HIV-1 bound NBD-556 efficiently.
Apparently, the gp120 change (N197S or ⌬V1/V2) that allows
CD4 independence compensates for the lack of histidine 66
and allows NBD-556 to bind gp120 and drive it into the CD4bound conformation. The magnitudes of the NBD-556-induced entropic and enthalpic changes in CD4-independent
gp120 are lower than those observed for CD4-dependent
gp120, consistent with a model in which the former gp120
glycoproteins have spontaneously negotiated a portion of the
conformational transition to the CD4-bound state.
What is the structural explanation for the observed effects of
the H66N change? As the H66N alteration can exert phenotypes independently of the gp120 V1/V2 variable loops, insights into histidine 66 function should be possible without
consideration of the V1/V2 loops, which have been deleted
from the “gp120 core” proteins for which structures are currently available (11, 47, 48). Although CD4-bound structures
of the HIV-1 gp120 core and unliganded structures of the SIV
gp120 core have been determined, the gp120 N-terminal segment containing histidine 66 was deleted from these constructs
to allow crystallization (11, 48). Recently, however, the structure of the HIV-1 gp120 glycoprotein with intact termini has
been solved in the CD4-bound state (Pancera et al., unpublished). The disulfide-bonded loop in which histidine 66 resides
is part of the gp120 inner domain (48, 95) (Fig. 9). In the
envelope glycoprotein complex, this disulfide-bonded loop is
thought to be located near the trimer axis and thus may be
proximal to the gp41 ectodomain. Although some elements of
the gp120 inner domain are thought to contact gp41 (Pancera
et al., unpublished), the histidine 66 side chain is not surface
exposed in the CD4-bound conformation. Rather, histidine 66
projects from the ␣0 helix in the disulfide-bonded loop into the
interior of the inner domain, contacting residues phenylalanine
210 and proline 212 (Fig. 9). Modeling of the wild-type and
H66N gp120 glycoproteins suggests that histidine 66 makes
stacking interactions with phenylalanine 210 and proline 212
that are predicted to stabilize the CD4-bound conformation
(see Fig. S7 in the supplemental material). These interactions
are lost upon substitution of an asparagine residue at position
66, resulting in destabilization of the CD4-bound state. The
modeling predictions are consistent with multiple observations, discussed above, that suggest that the H66N gp120 spontaneously samples the CD4-bound conformation less efficiently
than the wild-type gp120 glycoprotein. Examination of the
gp120-CD4 complex structure shown in Fig. 9 rules out any
direct contact between histidine 66 and CD4; based on recent
mapping of the NBD-556 binding site (52), histidine 66 is not
likely to contact this compound either. Thus, the effects of the
H66N change on CD4/NBD-556 interactions with the HIV-1
envelope glycoproteins likely arise indirectly, by influencing
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FIG. 9. Structure of the HIV-1 gp120 glycoprotein with complete N
and C termini in the CD4-bound conformation. The structure of the
HIV-1 gp120 glycoprotein bound to two-domain CD4 (Pancera et al.,
unpublished) is shown, from the approximate perspective of the trimer
axis in the assembled envelope glycoprotein trimer. The gp120 domains and the N and C termini are depicted. The inner domain and the
N and C termini have been implicated in the noncovalent interaction
with the gp41 ectodomain (32, 100). The ␣0 helix, in which histidine 66
resides, is distant from the CD4-binding region but near the gp41interactive surface of gp120. In the inset panels, the stacking interactions of histidine 66 (in the ␣0 helix) with proline 212 and phenylalanine 210 are shown from two perspectives. The images were created
with PyMOL (18).

associations within the inner domain that promote the attainment of the CD4-bound state. Of interest, the H66N change
does not affect the on-rate of the CD4 interaction with gp120,
which is thought to involve contacts primarily between CD4
and the gp120 outer domain (54). Rather, H66N increases the
dissociation rate of the gp120-CD4 complex. This observation
is consistent with a model in which the folding of the gp120
inner domain and bridging sheet stabilizes the complex with
CD4. Thus, histidine 66, by contributing to interactions within
the gp120 inner domain, helps gp120 to achieve the CD4bound conformation from its previously unliganded state.
How might the H66N change prolong the stability of the
activated state induced on the viral envelope glycoproteins by
sCD4? The longevity of this activated state of infectivity has
recently been shown to be correlated with the duration of
sCD4-induced exposure of gp41 ectodomain sequences (30).
Stabilization of this activated intermediate would presumably
require modification of the gp120-gp41 interactions involved in
governing conformational transitions in the envelope glycoproteins. Histidine 66 is strategically positioned between the putative gp41-interactive surface of gp120 and the binding site for
CD4 and is thus potentially available to influence the consequences of CD4 binding on gp41 conformation. However, in
the CD4-bound state, the histidine 66 side chain is completely
buried and therefore cannot contact gp41. It is possible that
the interactions of histidine 66 with other inner domain residues could indirectly influence the spatial relationship of gp120
and gp41. Alternatively, in the unliganded gp120 glycoprotein
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in the trimeric envelope glycoprotein complex, histidine 66 and
the surrounding disulfide-bonded loop may exist in a conformation that allows more direct contacts with the gp41 glycoprotein. Future studies will examine these possibilities.
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